rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BLRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      BioLineRx Enters into $5.6 Million Royalty Monetization Transaction with Soleus Capital
      16h agoYahoo FinanceBLRX
      BioLineRx initiates fourth cohort in GLIX1 brain tumor trial
      Nov 16Investing.comBLRX
      BioLineRx, Hemispherian report GLIX1 data at ESMO 2026
      Oct 23Investing.comBLRX
      BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026
      Oct 23Yahoo FinanceBLRX
      BioLineRx and Hemispherian to present GLIX1 data at SNO meeting
      Oct 8Investing.comBLRX
      BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day
      Oct 8MorningstarBLRX
      BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day – Company Announcement - FT.com
      Oct 8Financial TimesBLRX
      BioLineRx, Hemispherian to present GLIX1 data at EANO meeting
      Sep 10Investing.comBLRX
      BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)

      BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Hemispherian AS, a clinical-stage oncology company developing novel small molecule therapeutics, today announced that two abstracts featuring GLIX1 have been accepted for presentation, including one selected for oral presentation highlighting the preclinical efficacy of GLIX1 in orthotopic glioblastoma models, at the 21st Meeting of the Europe

      Sep 10Yahoo FinanceBLRX
      BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) – Company Announcement - FT.com
      Sep 10Financial TimesBLRX
      Exclusive BAC Article: BioLineRx; Futility Analysis Motixafortide PDAC 2026, GLIX1 Phase 1/2 Data 2026/2027, Potential PARP Collaboration, And Catalysts (NASDAQ:BLRX)

      I believe that a good speculative biotech to go over for the Exclusive BAC Subscribers Article would be BioLineRx (BLRX).

      Sep 2Seeking AlphaBLRX
      BLRX: New GLIX1 Data Touts Synergies

      By John Vandermosten, CFA NASDAQ: BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ: BLRX) reported second quarter 2026 financial and operational results in an August 31 st press release. For the quarter, it produced license revenues of $294,000 and a net loss of $4.3 million. The joint venture (JV) with Hemispherian, which is developing GLIX1, has begun enrolling the second of five

      Sep 1Yahoo FinanceBLRX
      Earnings call transcript: BioLineRx Q2 2026 revenue flat as GLIX1 advances
      Aug 31Investing.comBLRX
      BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
      Aug 31MorningstarBLRX
      BioLine Rx Ltd (BLRX) (Q2 2026) Earnings Call Highlights: Advancing GLIX1 Pipeline and ...
      Aug 31Yahoo FinanceBLRX
      BioLineRx Raises $3.75 Million in Registered Direct Offering, Retires ATM Facility

      Detailed price information for Biolinerx Ltd ADR (BLRX-Q) from The Globe and Mail including charting and trades.

      Aug 29The Globe and MailBLRX
      BioLineRx stock falls on $3.75M share offering plan
      Aug 28Investing.comBLRX
      BioLineRx raises $3.75 million in registered direct offering
      Aug 28Investing.comBLRX
      BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement

      BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into a definitive agreement for the purchase of an aggregate of 1,348,921 of the Company's American Depositary Shares (ADSs) (or ADS equivalents) at a purchase price of $2.78 per ADS (or per ADS equivalent) through a registered direct offering. In addition, the Company has agreed t

      Aug 28Yahoo FinanceBLRX
      BioLineRx to Report Second Quarter 2026 Results on August 31, 2026
      Aug 25MorningstarBLRX

      This is the newest page. Registered accounts read further back.